A Molecule Found in Python Blood Could Pave the Way for New Obesity Treatments.

Discovery of the pTOS Molecule

According to TSN.ua: A team of researchers has identified a molecule in the blood of Burmese pythons, named pTOS, that may serve as the foundation for next-generation anti-obesity drugs. This molecule significantly influences appetite, with pTOS levels surging more than 1,000-fold after a meal. In laboratory experiments, pTOS was shown to reduce food intake in obese mice, offering a promising new avenue for weight-loss therapies.

Key Findings from the Study

The research focused on young Burmese pythons weighing between 1.5 and 2.5 kg, a species known for its ability to survive without food for months—and sometimes over a year. Before the experiment, the snakes were subjected to a 28-day fasting period. The analysis revealed more than 200 molecules whose levels increased after eating, with pTOS showing the most dramatic rise, exceeding 1,000 times its baseline concentration.

During the trial, obese mice given pTOS consumed significantly less food, resulting in an approximate 9% loss of body weight over 28 days. Importantly, pTOS operates through a mechanism distinct from GLP-1-based drugs, opening up new possibilities for developing anti-obesity medications.

The discovery of pTOS has the potential to reshape how obesity—a major global health crisis—is treated. As the demand for effective weight management solutions continues to grow, research into pTOS could mark a critical advancement in the field. Further studies will be essential to evaluate the safety and efficacy of pTOS in clinical settings.